Navigation Links
LA BioMed receives Grand Challenges Explorations grant
Date:5/15/2012

LOS ANGELES (May 15, 2012) The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) announced today that it is a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation. Frans J. Walther, M.D., Ph.D., FAAP, LA BioMed lead investigator and Professor of Pediatrics at UCLA, will pursue an innovative global health and development research project, titled "Aerosol Delivery of Synthetic Lung Surfactant."

Grand Challenges Explorations (GCE) funds individuals worldwide to explore ideas that can break the mold in how we solve persistent global health and development challenges. Dr. Walther's project is one of over 100 Grand Challenges Explorations Round 8 grants announced today by the Bill & Melinda Gates Foundation.

"Grand Challenges Explorations encourages individuals worldwide to expand the pipeline of ideas where creative, unorthodox thinking is most urgently needed," said Chris Wilson, director of Global Health Discovery and Translational Sciences at the Bill & Melinda Gates Foundation. "We're excited to provide additional funding for select grantees so that they can continue to advance their idea towards global impact."

To receive funding, Dr. Walther and other Grand Challenges Explorations Round 8 winners demonstrated in a two-page online application a bold idea in one of five critical global heath and development topic areas that included agriculture development, immunization and nutrition. Applications for the current open round, Grand Challenges Explorations Round 9, will be accepted through May 15, 2012.

Seven percent of all infants are born prematurely. Half of them develop breathing problems because their lungs are immature and lack surfactant, a substance consisting of lipids and proteins that reduces surface tension in the lungs and is pivotal in keeping lungs open during expiration. The application of continuous positive airway pressure (CPAP) via the nose throughout the respiratory cycle during spontaneous breathing has revolutionized the treatment of respiratory failure in premature infants.

Nasal CPAP assists in opening and keeping open the lungs from birth onwards and is applicable in both high and low technical settings. If this noninvasive approach fails, the next step is to insert a breathing tube, start mechanical ventilation, and instill a clinical lung surfactant into the airways. This approach is not only invasive, but may damage the lungs and requires advanced skills and equipment. Delivery of an advanced synthetic lung surfactant as an aerosol will open up the possibility to use this rescue treatment in a non-invasive way. The combination of nasal CPAP and aerosolized synthetic lung surfactant will first be tested in a laboratory setting. If successful , this new approach will be further developed for clinical use.


'/>"/>

Contact: Diana Soltesz
diana@dsmmedia.com
818-592-6747
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. Biomedical researchers receive Hartwell Foundation awards
2. LA BioMeds Dr. John Tsuang examines effects of Ibudilast and metamphetamines
3. LA BioMed investigators uncover new advancements in cardiovascular medicine
4. CCNYs Robert Alfano wins first biomedical optics award
5. LA BioMed investigators lead first survey to determine hospital EDs pediatric readiness
6. Nations largest federation of biological and biomedical organizations welcomes 2 new members
7. Virginia Techs Rylander wins national biomedical engineering award
8. Swedish people are quick to adopt JoVE, a video journal for biomedical sciences
9. Report calls for creation of a biomedical research and patient data network for more accurate classification of diseases, move toward precision medicine
10. LA BioMeds Dr. Ronald Oudiz impacting lives of those with pulmonary hypertension
11. Dartmouth Med School lands $11M grant for regional biomedical research center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... ... LLC (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions ... definitive agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an ... an educational webinar, they will present the line of epMotion automated liquid handling ... easy you can automate everyday pipetting tasks. , Ideal for scientists and lab ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a Houston ... east Texas, is launching a regional charity effort to provide publicity assistance and ... Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations that ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Golseth Agency, a Texas based ... area, is spearheading a regional charity campaign organized to provide support to Christina Upchurch ... of this year, Christina and her children returned from out of town to find ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that rids the ... efforts with its product now available through Jet.com. , After 25 years of ... powdered drink is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 15, 2017 AccuGenomics, Inc., a diagnostic company ... announced that the company has provided an AccuKit to ... Carolina at Chapel Hill and to Qura Therapeutics for ... and quantify HIV reservoir and viral expression in human ... HIV Cure Center is a joint initiative between the ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... June 30, 2017.  All comparisons, unless otherwise noted, are to ... Second Quarter 2017 Highlights include: ... an increase of 3.5% Total prescriptions dispensed ... of 7.5% versus 7.6% Gross profit ...
Breaking Medicine Technology: